← back to search

Eric Wang

University of Southern California · US
Area of research
Molecular Biology · Hematology
Research interest
Research interests include RNA Research and Splicing, Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, and Cancer-related molecular mechanisms research.
h-index
34
citations
7,612
works
170
NIH funding
primary concept
Biology
email

Recent publications

Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia.
2026cited by 0position: contributordoi
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias
Cell 2025cited by 32position: middledoi
HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia
Blood 2025cited by 12position: middledoi
Uncovering Novel lncRNAs Linked to Melanoma Growth and Migration with CRISPR Inhibition Screening.
2025cited by 0position: contributordoi
An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance.
2025cited by 0position: contributordoi
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Science 2024cited by 143position: middledoi
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition
Leukemia 2024cited by 9position: middledoi
Non-genetic mechanisms of drug resistance in acute leukemias.
2024cited by 8position: contributordoi
Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
Blood 2024cited by 1position: middledoi
Cell-type-specific prediction of 3D chromatin organization enables high-throughput in silico genetic screening
Nature Biotechnology 2023cited by 124position: middledoi
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia.
2023cited by 58position: contributordoi
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
2022cited by 200position: contributordoi
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Cancer Discovery 2022cited by 92position: middledoi
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation.
2022cited by 81position: contributordoi
Valine tRNA levels and availability regulate complex I assembly in leukaemia.
2022cited by 78position: contributordoi
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia
Nature Immunology 2022cited by 53position: middledoi
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia.
2022cited by 47position: contributordoi
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation
Cancer Discovery 2022cited by 36position: middledoi
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.
2022cited by 27position: contributordoi
Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
Blood 2022cited by 17position: middledoi
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
Cell 2021cited by 274position: middledoi
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
2021cited by 242position: contributordoi
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
Nature Genetics 2021cited by 109position: middledoi
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.
2021cited by 88position: contributordoi
Valine tRNA levels and availability regulate complex I assembly in leukaemia
Nature 2021cited by 80position: middledoi
Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation
Cell stem cell 2021cited by 66position: firstdoi
Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation.
2021cited by 57position: contributordoi
RNA Splicing and Cancer
Trends in cancer 2020cited by 247position: firstdoi
RNA Splicing and Cancer.
2020cited by 181position: contributordoi
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia
Cancer Discovery 2020cited by 101position: middledoi

Grants

MFB: Defining a molecular grammar for ribonucleoprotein particle trafficking
NSF2515694$1,200,0002025–2028PIRePORTER

Frequent collaborators

Iannis Aifantis · NYU Langone Health13 papers (2016–2026)Aristotelis Tsirigos · NYU Langone’s Laura and Isaac Perlmutter Cancer Center6 papers (2019–2026)Aristotelis Tsirigos · NYU Langone Health6 papers (2016–2023)Sydney X. Lu · Stanford University5 papers (2019–2022) · 4 papers (2022–2026) · 4 papers (2022–2026)Omar Abdel-Wahab · Presbyterian Hospital4 papers (2021–2025)Robert K. Bradley · University of Toledo4 papers (2021–2025)Palaniraja Thandapani · New York University4 papers (2021–2023)Andreas Kloetgen · New York University4 papers (2019–2021)Palaniraja Thandapani · The University of Texas MD Anderson Cancer Center3 papers (2022–2025)Christopher R. Vakoc · University Children's Hospital Zurich3 papers (2012–2019)Omar Abdel‐Wahab · Presbyterian Hospital3 papers (2019–2022)Matthew T. Witkowski · University of Colorado Denver3 papers (2021–2022)Xufeng Chen · Zhejiang Chinese Medical University3 papers (2019–2021)Justin Taylor · University of Miami3 papers (2021–2024)Sadik Karma · Jackson Laboratory2 papers (2025–2026)Zhiping Zhang · Tongde Hospital of Zhejiang Province2 papers (2025–2026)Raoul Tibes · AstraZeneca (United Kingdom)2 papers (2019–2019)Sakthi Harini Rajendran · Jackson Laboratory2 papers (2025–2026)